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ABSTRACT
Objectives: The recognition of coronary artery
disease (CAD) among patients who report chest pain
remains difficult in primary care. This study
investigates the association between chest pain
(specified, unspecified or musculoskeletal) and
prodromes (dyspepsia, fatigue or dyspnoea), with first-
ever acute CAD, and increased longer term
cardiovascular risk.
Design: Cohort study.
Setting: Anonymised clinical data recorded
electronically by general practitioners from 140 primary
care surgeries in London (UK) between April 2008 and
April 2013.
Participants: Data were extracted for all patients aged
30 years and over at the beginning of the study period,
registered in the surgeries.
Main outcome measures: Clinical data included
chest pain, dyspepsia, dyspnoea and fatigue, first-ever
CAD and long-term cardiovascular risk (QRisk2).
Regression models were used to analyse the
association between chest pain together with
prodromes and CAD and QRisk2≥20%.
Results: 354 052 patients were included in the study.
4842 patients had first-ever CAD of which 270 reported
chest pain in the year before the acute event. 257 019
patients had QRisk2 estimations. Chest pain was
associated with a higher risk of CAD. HRs: 21.12
(16.68 to 26.76), p<0.001; 7.51 (6.49 to 8.68),
p<0.001; and 1.84 (1.14 to 3.00), p<0.001 for
specified, unspecified and musculoskeletal chest pain.
Dyspepsia, dyspnoea or fatigue was also associated
with a higher risk of CAD. Chest pain of all subtypes,
dyspepsia and dyspnoea were also associated with an
increased 10-year cardiovascular risk of 20% or more.
Conclusions: All patients with chest pain, including
those with atypical symptoms, require careful
assessment for acute and longer term cardiovascular
risk. Prodromes may have independent diagnostic
value in the estimation of cardiovascular disease risk.
INTRODUCTION
Coronary artery disease (CAD) is the leading
cause of global mortality, accounting for 13%
of deaths across the world.1 Chest pain is a
common presenting symptom of CAD.
However, the recognition of CAD among
those who report chest pain remains difﬁcult
in primary care as chest pain only represents
CAD in 8%2 to 11%3–5 of the patients. The
guidelines of both the UK National Institute
for Health and Care Excellence (NICE) and
the American Heart Association acknowledge
that clinical assessment may be sufﬁcient to
conﬁrm or exclude the diagnosis of CAD.6 7
The NICE guidelines recommend the estima-
tion of risk of CAD based on the typicality of
the pain, age, gender and cardiovascular
(CV) risk factors, and suggest the consider-
ation of an alternative diagnosis if the esti-
mated risk is below 10%.6 Many patients
referred to secondary care are now offered
investigations which have high costs and
some involve exposure to ionising radi-
ation.6 8–10 This care pathway emphasises the
relevance of the initial clinical assessment in
Strengths and limitations of this study
▪ Chest pain of all clinical presentations (specified,
unspecified and musculoskeletal) is associated
with an increased risk of acute coronary artery
disease (CAD) and increased longer term cardio-
vascular (CV) risk.
▪ Dyspepsia and dyspnoea in patients with chest
pain are associated with acute CAD and longer
term CV risk. Fatigue is also associated with
increased risk of CAD.
▪ The data analysed in this study are derived from an
almost complete population and not selected indivi-
duals or organisations; therefore, they provide the
least biased sample frame and are likely to be repre-
sentative of similar ethnically diverse populations.
▪ It was also possible to analyse several variables
simultaneously, allowing the effect of multiple
symptoms to be assessed.
▪ It is possible that this study underestimates the
incidence of CAD as death outside the hospital
may not always be recorded in the general practi-
tioners’ records. Patients who reported chest pain
were more likely to have QRisk2 estimations;
therefore, the association between the symptoms
and the long-term CV risk may be overestimated.
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primary care. Both unnecessary referral and failure to
diagnose CAD are important issues from a resource and
clinical outcome perspective.11
The initial clinical assessment in primary care should
include the consideration of the typicality of chest pain.6
Clinicians appropriately refer central chest pain with
shoulder radiation, or avoid referring typical musculo-
skeletal chest pain. However, there is a large grey area of
unspeciﬁed chest pain that ﬁts neither of these categor-
ies, particularly in older people at higher risk. The
current recommendations for estimating the risk of CAD
in patients with chest pain, acknowledging the typicality
of symptoms, are based on a single secondary care study
published in 1993.12 However, it is reported in the guide-
lines that this study may overestimate the risk of CAD in
primary care.6 12 In addition, about half of the patients
with CAD also report other prodromal symptoms to
their general practitioner in the months before the
acute event3 13–16 with dyspepsia, dyspnoea and fatigue
among the most frequently reported.14 16 There is little
information on the diagnostic and prognostic value of
such symptoms.
There are a number of validated tools, such as
QRisk2, for the assessment of long-term CV risk in
asymptomatic primary care patients.17 However, it is
unclear whether these tools could also be used in
patients with chest pain to estimate the risk of acute
CAD. We wished to undertake preliminary work to
explore the association between type of chest pain,
together with prodromal symptoms, and CV risk. This
will inform subsequent research, using a larger data set,
in which a tool for prediction of acute CAD in primary
care patients with chest pain might be derived.
This paper investigates the association between chest
pain (speciﬁed, unspeciﬁed and musculoskeletal) and
prodromal symptoms (dyspepsia, dyspnoea and fatigue),
with ﬁrst-ever acute CAD. The association between chest
pain and prodromal symptoms with longer term CV risk
(QRisk2 scores) is also examined.17
METHODS
The study conformed to the STROBE (Strengthening
the Reporting of Observational Studies in
Epidemiology) study design recommendations.18
The study was based on patients living in three inner
boroughs of east London (UK), registered with local
general practitioners (GPs). This area had a population
of 908 096 in April 2013 and over half of the patients
were of non-white ethnicity. Anonymised clinical and
demographic data recorded in GPs’ electronic health
records between 1 April 2008 and 1 April 2013 were
extracted using EMIS web software for all patients aged
30 years and over at the beginning of the study period.
Patients from 140 of the 144 GP surgeries in the bor-
oughs were used for the analysis (four surgeries used a
different computer system and therefore were not
included). Sociodemographic variables extracted
included age, gender and self-reported ethnic group.
The Townsend deprivation score, a measure of material
deprivation derived from the UK Census at a small area
level, that strongly correlates with standardised mortality
ratios, was also recorded.19 Age was grouped into ﬁve
categories of 35–44 years, 45–54, 55–64, 65–74, and 75
and older. Ethnicity was grouped into four categories:
white, south Asian, black African/Caribbean and other.
Individuals of mixed ethnicity were grouped with the
relevant ethnic minority group. Clinical data included
routinely recorded chest pain, prodromal symptoms and
a report of a ﬁrst-ever CAD in the electronic medical
record. Chest pain was grouped into three categories of
speciﬁed, unspeciﬁed and musculoskeletal. Table 1
shows the symptoms coded by the GPs that were used to
deﬁne each of these categories in this study.
Prodromal symptoms included dyspepsia, dyspnoea and
fatigue. The terms coded by the GPs that were used in this
study to deﬁne CAD and each prodromal symptom are pre-
sented in online supplement 1. Additional clinical data
used in the analyses included long-term CV risk, assessed
with QRisk2 10-year CV risk scores.17 The QRisk2 score for
prediction of CV disease within 10 years was stratiﬁed into
lower (0–9%), medium (10–19%) and high risk (≥20%).17
The associations between chest pain, dyspepsia, dys-
pnoea or fatigue and ﬁrst-ever reported CAD in the year
succeeding the onset of symptoms were investigated.
CAD was reported in the year after the start of symptoms
because it was considered both observations within that
period of time could be assumed to be clinically related.
When prodromes (dyspepsia, dyspnoea or fatigue) had
been reported in the 12 months before chest pain, and
they were independently associated with CAD, they were
combined with chest pain. The associations between the
combination of chest pain and prodromes with ﬁrst-ever
CAD were also estimated.
Within the 5 years of the study period, the associations
of chest pain, dyspepsia, dyspnoea or fatigue with high
Table 1 General practitioner notes used to define each
category of chest pain
Chest pain
category
Read codes from clinical notes
included in each variable
Specified chest pain Ischaemic chest pain
Central chest pain
Precordial pain
Parasternal pain
Chest pain on exertion
Retrosternal pain
Unspecified chest
pain
Anterior chest wall pain
Chest wall pain
Chest pain not otherwise specified
Atypical chest pain
Chest pain unspecified
Musculoskeletal
chest pain
Rib pain
Pleuritic pain
Painful breathing-pleurodynia
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CV risk (QRisk2≥20%) were investigated. When pro-
dromes had been reported in the 12 months before
chest pain, and they were independently associated with
QRisk2>20%, they were combined with chest pain. The
associations between the combination of chest pain and
prodromes with QRisk2>20% were also estimated.
For patients with chest pain or prodromes recorded
more than once, only the most recent episode of chest
pain or the most recent prodrome, before the ﬁrst-ever
CAD or QRisk2 measurement, was included in the ana-
lysis. For those who had more than one QRisk2 estima-
tion during the study period, only the ﬁrst one was
included in the analyses. Cox regression was used when
CAD was the outcome. Cox regression describes how the
risk of CAD changes over time in response to explana-
tory covariates (chest pain or prodromes). Results of
Cox regression are presented in HRs, which are the
expression of the risk of CAD occurring in patients with
chest pain or prodromes as a ratio of the risk of CAD in
patients without these symptoms. Models for the analysis
of CAD were adjusted for age, gender, ethnicity and
Townsend deprivation score. These variables were
included in the models as they were considered poten-
tial confounders. Models for the analyses of QRisk2 were
not adjusted as the QRisk2 algorithm already includes
age, gender, ethnicity and Townsend score. SEs were
adjusted for clustering by family practice.
RESULTS
In total, 354 052 patients aged 30 years or older were
included in the study. During the 5-year study period,
14 222 (4.0%) patients reported chest pain to their
general practitioner, 70 110 (19.8%) patients had
reported dyspnoea, dyspepsia or fatigue and 257 019
(72.6%) patients had a QRisk2 estimation. Table 2 shows
the sociodemographic and clinical characteristics of
patients with chest pain and prodromes.
Among the 4842 patients with ﬁrst-ever CAD, 270
(5.6%) reported chest pain to the general practitioner
in the year before the acute event. Within the 12 months
prior to the CAD event, 70 patients had a diagnosis of
speciﬁed chest pain (25.9%), 187 had a diagnosis for
unspeciﬁed chest pain (69.2%) and 17 had a diagnosis
for musculoskeletal pain (6.3%). Some patients had
more than one chest pain event coded in the preceding
12 months. For the purposes of calculating the risk of
CAD after experiencing multiple chest pain events, the
date of the chest pain closest to the CAD event was used.
In the year preceding the CAD, 495 (10.2%) patients
had reported prodromes. Dyspepsia was reported by 232
(46.9%) patients, dyspnoea by 235 (47.5%) and fatigue
by 54 (10.9%) patients, with some patients having more
than one prodrome recorded prior to CAD. Chest pain
was independently (after adjusting for confounders)
associated with a higher risk of CAD within the following
year as shown in table 3. This association was signiﬁcant
for all types of chest pain but strongest for patients
reporting speciﬁed chest pain. Dyspepsia, dyspnoea or
fatigue was also independently associated with a higher
risk of CAD within the following year. The presence of
chest pain of all subtypes in combination with dyspepsia,
dyspnoea or fatigue was associated with an increased risk
of CAD in the following year (table 3).
Among the 2027 patients with 10-year CV risk of 20%
or more as deﬁned by QRisk2 reported after chest pain
or prodromes, prior to a QRisk2 value of 20% or greater
being recorded on the patient record, 195 (9.6%) had a
diagnosis of speciﬁed chest pain, 1437 (70.9%) had
a diagnosis of unspeciﬁed chest pain and 492 had
Table 2 Characteristics of patients with chest pain and prodromes
N=354 052 Chest pain Per cent Prodromes Per cent (95% CI)
All patients aged 30+ on 1 April 2008 14 222 100 70 110 100
Female 7750 54.5 41 402 59.1
Age
35–44 4480 31.5 24 447 34.9
45–54 4265 30.0 19 204 27.4
55–64 2876 20.2 12 392 17.7
65–74 1534 10.8 7532 10.7
75+ 1064 7.5 6535 9.3
Ethnicity
White 5394 37.9 25 277 36.1
South Asian 4863 34.2 25 709 36.7
Black 2770 19.5 12 987 18.5
Other 679 4.8 3333 4.8
Unknown 516 3.6 2804 4.0
Townsend score (median and range) 6.1 (−2.92 to 9.68) 6.1 (−5.28 to 9.58)
CAD in the 12 months after chest pain/prodromes 270 1.9 (1.7 to 2.1) 495 0.71 (0.65 to 0.77)
QRisk2 value not recorded 2580 18.1 15 007 21.4
QRisk2 value <20% after chest pain/prodromes 7107 50.0 (0.49 to 0.51) 34 052 48.6 (48.2 to 48.9)
QRisk2 value ≥20% after chest pain/prodromes 2027 14.3 (13.9 to 15.0) 10 337 14.7 (14.4 to 15.0)
CAD, cardiovascular disease.
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a diagnosis of musculoskeletal chest pain (24.3%), with
some patients having more than one chest pain event
recorded. Of the 10 337 patients who had CV risk of
20% or more after any prodrome, the most recent pro-
drome recorded was dyspepsia for 7022 (67.9%), dys-
pnoea for 2865 (27.7%) and fatigue for 1977 (19.1%)
cases, with some patients having more than one pro-
drome recorded. Chest pain of all subtypes was asso-
ciated with a high CV risk of 20% or more. Dyspepsia
and dyspnoea were also associated with a high CV risk of
20% or more. Finally, the presence of dyspepsia or dys-
pnoea in combination with chest pain of all subtypes was
associated with a high long-term CV risk of 20% or more
(table 4).
DISCUSSION
Our study suggests that all presentations of chest pain
were associated with an increased risk of CAD, within
the next year, and increased longer term CV risk. These
associations were strongest for speciﬁed chest pain, but
importantly were also present for other categories of
chest pain. Dyspepsia and dyspnoea were also associated
with CAD and longer term CV risk. Fatigue was asso-
ciated with increased risk of CAD but not with longer
term CV risk.
This study has strengths and weaknesses. The data are
derived from an almost complete population and not
selected individuals or organisations and are likely to be
representative of similar ethnically diverse populations.
The inclusion of the entire local population in a large
data set provides the least biased sampling frame. In
contrast with many previous articles, this study has a
high number of cases and improved statistical
power.2 13 16 It was also possible to analyse several vari-
ables simultaneously, allowing the effect of multiple
symptoms to be assessed. CAD may have been over-
reported in our study, since we used an extensive list of
terms for its deﬁnition. However, this broad deﬁnition of
CAD probably minimised the number of CADs that were
missed. The categorisation of chest pain used in this
paper included pain location, which has been ques-
tioned as a predictor of CAD.20 Structured data entry
templates and clinical facilitation in the east London
practices studied enabled routine entry of high-quality
data using agreed code sets for recording CV risk
Table 3 Risk of cardiovascular disease (CAD) within 1 year of chest pain, dyspepsia, dyspnoea or fatigue
N
CAD with
in 1 year
Median time
to CAD in
months (SD) Adjusted HR (95% CI) p Value
Any chest pain 14 222 270 3.3 (3.1) 2.32 2.11 to 2.56 <0.001
Specified chest pain 1136 70 2.6 (2.8) 21.12 16.68 to 26.76 <0.001
Unspecified chest pain 10 226 187 3.3 (3.0) 7.51 6.49 to 8.68 <0.001
Musculoskeletal chest pain 3418 17 5.8 (3.8) 1.84 1.14 to 3.00 0.001
Dyspepsia 45 785 232 5.7 (3.6) 2.21 1.94 to 2.51 <0.001
Dyspnoea 14 877 235 3.8 (3.6) 4.92 4.30 to 5.61 <0.001
Fatigue 19 710 54 6.4 (3.2) 1.36 1.04 to 1.78 0.024
Any prodrome+specified chest pain 134 5 3.3 (1.5) 12.84 5.34 to 30.87 <0.001
Any prodrome+unspecified chest pain 1098 37 3.8 (3.0) 11.17 8.08 to 15.45 <0.001
Any prodrome+musculoskeletal pain 335 8 10.8 (23.1) 2.52 1.26 to 5.04 0.009
Table 4 Odds of having QRisk2≥20% or more in patients with chest pain, dyspepsia, dyspnoea or fatigue
N
QRisk2
≥20%
Median time to
QRisk2≥20% in
months (SD) Crude OR (95% CI) p Value
Any chest pain 9134 2027 30.0 (19.3) 1.43 1.36 to 1.50 <0.001
Specified chest pain 688 195 31.9 (19.5) 1.96 1.66 to 2.31 <0.00
Unspecified chest pain 6650 1437 31.2 (19.7) 1.37 1.29 to 1.45 <0.001
Musculoskeletal chest pain 2125 492 28.3 (18.3) 1.49 1.35 to 1.65 <0.001
Dyspepsia 29 492 7022 35.2 (19.3) 1.65 1.60 to 1.70 <0.001
Dyspnoea 8418 2865 30.2 (18.9) 2.67 2.54 to 2.78 <0.001
Fatigue 12 398 1977 30.4 (19.3) 0.93 0.89 to 0.98 0.006
Specified chest pain+dyspepsia or
dyspnoea
99 20 34.4 (16.7) 2.53 1.48 to 4.34 0.001
Unspecified chest pain+dyspepsia or
dyspnoea
835 147 30.1 (19.6) 1.75 1.45 to 2.11 <0.001
Musculoskeletal chest pain+dyspepsia or
dyspnoea
251 54 30.8 (15.3) 2.30 1.66 to 3.18 <0.001
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factors. Although CAD diagnoses were not adjudicated,
the inclusion of this diagnosis is reviewed by local clini-
cians as part of their national Quality and Outcome
Framework audit returns, which provide some validation
of the diagnosis. It is possible that these underestimate
total CAD as death outside hospital may not always be
recorded in general practitioners’ records.
Clinicians are likely to be aware that patients reporting
speciﬁed chest pain have a greater risk of CAD than
those with atypical symptoms. These patients will require
assessment in secondary care in most cases. However,
unspeciﬁed and musculoskeletal chest pain should not
be disregarded as these symptoms are associated with
the risk of CAD above 10%. These results are consistent
with the guidance for risk stratiﬁcation12 included in the
NICE guidelines.6 It has been reported that the associ-
ation between atypical chest pain and CAD is strongest
in older patients, south Asians and those affected by dia-
betes.21 Future studies may provide a more accurate esti-
mation of the risk of CAD in primary care patients with
chest pain in association with prodromal symptoms and
other CV risk factors. It should also be noted that the
proportion of patients with CAD who reported chest
pain or prodromes to their GP in the year before the
acute event was small. The natural history of CAD in the
large proportion of patients who were not seen in
primary care requires further clinical and epidemio-
logical studies.
The factors that cause the association between chest
pain and acute events are likely to explain its association
with increased CV risk in the longer term. The typicality
of symptoms appears to have less impact on the longer
term CV risk. It is possible that some of the prodromal
symptoms or episodes of chest pain observed within a
year of CAD were not clinically related to it. Future
studies may investigate whether the associations between
chest pain, prodromes and CAD are similar when a
shorter period of time (ie, three months) is observed. It
should be noted that, in our sample, patients who
reported chest pain were more likely to have QRisk2 esti-
mations; therefore, the association between the symp-
toms and the long-term CV risk may be overestimated.
The association between dyspepsia, dyspnoea or fatigue
with CAD could also be partially explained by misdiag-
nosis in some patients, for example, angina being diag-
nosed as dyspepsia.22 Medication that prevents CV
events, such as aspirin, may not have been prescribed to
patients with dyspepsia,23 possibly increasing the rate of
CAD among them.
A signiﬁcant number of missed opportunities in the
early management of CAD has been observed by other
authors in primary care.16 Scores to estimate CV risk rep-
resent an attractive instrument to identify patients at
high risk, both acutely and in the long term, and
prompt more aggressive interventions.16 There are a
number of reasons why the development of a risk score,
using combinations of clinical data,24 for patients with
chest pain in primary care may be appropriate. Patients
with suspected CAD who are inadequately managed may
have inappropriate and harmful investigations at high
cost. Alternatively, those who are missed may have a pre-
ventable CV event. There are already validated and
widely used scores predicting long-term CV risk in
asymptomatic patients.17 There are also scores for risk
assessment in patients with chest pain, which provide
useful evidence for ruling out CAD.12 25–30 However,
only two of the available scores, routinely used in clinical
practice, have been derived and validated in primary
care.25 26 Electronic medical records represent clinical
data sets of good quality, with larger samples than in
most previous studies,11 and may provide a suitable basis
to develop new and accurate scores for the diagnosis of
acute and longer term CAD. The typicality of chest pain,
together with the presence of dyspepsia and dyspnoea,
might be considered in the further development of clin-
ical decision rules based on risk of CAD for patients with
chest pain but would require further validation.
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